Inflammatory Bowel Diseases: Ulcerative Colitis and Crohn's Disease

The Autoimmune Diseases, Fourth Edition

Volumn , Issue , 2006, Pages 713,XXII-728,XXIII

  Palmon, Ron ^a   Mayer, Lloyd F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49549108050     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012595961-2/50055-X     Document Type: Chapter

References (126)

1. T. Ahmad, A. Armuzzi, M. Bunce, K. Mulcahy-Hawes, S.E. Marshall, T.R. Orchard, J. Crawshaw, O. Large, A. de Silva, J.T. Cook, M. Barnardo, S. Cullen, K.I. Welsh and D.P. Jewell (2002) The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122 854-866.
2. T. Ahmad, C.P. Tamboli, D. Jewell and J.F. Colombel (2004) Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126 1533-1549.
3. I. Ahnfelt-Ronne, O.H. Nielsen, A. Christensen, E. Langholz, V. Binder and P. Riis (1990) Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 98 1162-1169.
4. M. Allez, J. Brimnes, I. Dotan and L. Mayer (2002) Expansion of CD8+T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology 123 1516-1526.
5. L.G. Axelsson, E. Landstrom, T.J. Goldschmidt, A. Gronberg and A.C. Bylund-Fellenius (1996) Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm. Res. 45 181-191.
6. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D'Haens, A. Carbonez and P. Rutgeerts (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348 601-608.
7. H. Bantel, C. Berg, M. Vieth, M. Stolte, W. Kruis and K. Schulze-Osthoff (2000) Measalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol. 95 3452-3457.
8. J. Baron (2000) Inflammatory bowel disease up to 1932. Mt. Sinai. J. Med. 67 174-189.
9. D.J. Berg, J. Zhang, J.V. Weinstock, H.F. Ismail, K.A. Earle, H. Alila, R. Pamukcu, S. Moore and R.G. Lynch (2002) Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123 1527-1542.
10. V. Binder (1998) Genetic epidemiology in inflammatory bowel disease. Dig. Dis. 16 351-355.
11. J.F. Blanchard, C.N. Bernstein, A. Wajda and P. Rawsthorne (2001) Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. Am. J. Epidemiol. 154 328-335.
12. M. Boirivant, M. Marini, G. Di Felice, A.M. Pronio, C. Montesani, R. Tersigni and W. Strober (1999) Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116 557-565.
13. D.K. Bonen, D.L. Nicolae, T. Moran, M.A. Turkyilmaz, R. Ramos, R. Karaliukas, S.R. Brant, R.H. Duerr, B.S. Kirschner, S. Hanauer and J.H. Cho (2002) Racial differences in Nod2 variation: characterization of Nod2 in African-Americans with Crohn's disease. Gastroenterology 122 A29.
14. E.J. Boyko, D.R. Perera, T.D. Keopsell, E.M. Keane and T.S. Inui (1988) Effect of cigarette smoking on the clinical course of ulcerative colitis. Scand. J. Gastroenterol. 23 1147-1152.
15. B.M. Calkins (1989) A meta-analysis of the role of smoking in inflammatory bowel disease. Dig. Dis. Sci. 34 1841-1854.
16. N.A. Campbell, H.S. Kim, R.S. Blumberg and L. Mayer (1999) The nonclassical class I molecule CD1d associates with the novel CD8 ligand gp180 on intestinal epithelial cells. J. Biol. Chem. 274 26259-26265.
17. L.V. Chalifoux and R.T. Bronson (1981) Colonic adenocarcinoma associated with chronic colitis in cotton top marmosets, Saguinus oedipus. Gastroenterology 80 942-946.
18. M. Chamaillard, S.E. Girardin, J. Viala and D. Philpott (2003) Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell Microbiol. 5 581-592.
19. S. Colpaert, K. Vastraelen, Z. Liu, P. Maerten, C. Shen, F. Penninckx, K. Geboes, P. Rutgeerts and J.L. Ceuppens (2002) In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease. Eur. Cytokine Netw. 13 431-437.
20. H.S. Cooper, S.N. Murthy, R.S. Shah and D.J. Sedergran (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69 238-249.
21. N.J. Davidson, S.A. Hudak, R.E. Lesley, S. Menon, M.W. Leach and D.M. Rennick (1998) IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J. Immunol. 161 3143-3149.
22. B.K. Dieckgraefe and J.R. Korzenik (2002) Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colonystimulating factor. Lancet 360 1478-1480.
23. R. Duchmann, I. Kaiser, E. Hermann, W. Mayet, K. Ewe and K.H. Meyer zum Buschenfelde (1995) Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102 448-455.
24. J. Eaden, K.R. Abrams and J.F. Mayberry (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 526-535.
25. S. Edsbacker, M. Nilsson and P. Larsson (1999) A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone. Aliment Pharmacol Ther. 13 219-224.
26. R.O. Ehrhardt, B.R. Ludviksson, B. Gray, M. Neurath and W. Strober (1997) Induction and prevention of colonic inflammation in IL-2-deficient mice. J. Immunol. 158 566-573.
27. P.R. Fleshner, E.A. Vasiliauskas, L.Y. Kam, N.F. Fleshner, J. Gaiennie, M.T. Abreu-Martin and S.R. Targan (2001) High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 49 671-677.
28. J. George, D.H. Present, R. Pou, C. Bodian and P.H. Rubin (1996) The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am. J. Gastroenterol. 91 1711-1714.
29. S. Ghosh, E. Goldin, F.H. Gordon, H.A. Malchow, J. Rask-Madsen, P. Rutgeerts, P. Vyhnalek, Z. Zadorova, T. Palmer and S. Donoghue Natalizumab Pan-European Study Group (2003) Natalizumab for Active Crohn's Disease. N. Engl. J. Med. 348 24-32.
30. L. Ginzburg and G.D. Oppenheimer (1932) Non-specific granulomata of the intestines (inflammatory tumors and strictures of the bowel. Trans. Am. Gastro-Enterol. Assoc. 35 241-283.
31. S.E. Girardin, I.G. Boneca, J. Viala, M. Chamaillard, A. Labigne, G. Thomas, D.J. Philpott and P.J. Sansonetti (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278 8869-8872.
32. G.R. Greenberg, B.G. Feagan, F. Martin, L.R. Sutherland, A.B. Thomson, C.N. Williams, L.G. Nilsson and T. Persson (1994) Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N. Engl. J. Med. 331 836-841.
33. A. Greenstein, H.D. Janowitz and D.B. Sachar (1976) The extraintestinal complications of Crohn's disease and ulcerative colitis. Medicine 55 401-412.
34. W. Hale-White (1888) On simple ulcerative colitis and other rare intestinal ulcers. Guys Hosp. Rep. 3nd series 30 131-162.
35. J. Halfvarson, L. Bodin, C. Tysk, E. Lindberg and G. Jarnerot (2003) Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124 1767-1773.
36. J. Hampe, A. Cuthbert, P.J. Croucher, M.M. Mirza, S. Mascheretti, S. Fisher, H. Frenzel, K. King, A. Hasselmeyer, A.J. MacPherson, S. Bridger, S. van Deventer, A. Forbes, S. Nikolaus, J.E. Lennard-Jones, U.R. Foelsch, M. Krawczak, C. Lewis, S. Schreiber and C.G. Mathew (2001) Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357 1925-1928.
37. H. Hanai, F. Watanabe, M. Yamada, Y. Sato, K. Takeuchi, T. Iida, K. Tozawa, T. Tanaka, Y. Maruyama, I. Matsuhita, Y. Iwaoka, K. Kikuch and A.R. Saniabadi (2004) Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digesion 70 36-44.
38. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, J.F. Colombel, D. Rachmilewitz, D.C. Wolf, A. Olson, W. Bao and P. Rutgeerts (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 1541-1549.
39. F. Heller, I.J. Fuss, E.E. Nieuwenhuis, R.S. Blumberg and W. Strober (2002) Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17 629-638.
40. H.H. Herfarth, S.P. Mohanty, H.C. Rath, S. Tonkonogy and R.B. Sartor (1996) Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 96 836-845.
41. T. Hisamatsu, M. Suzuki, H.C. Reinecker, W.J. Nadeau, B.A. McCormick and D.K. Podolsky (2003) CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124 993-1000.
42. J.P. Hugot, M. Chamillard, H. Zouali, S. Lesage, J.P. Cezard, J. Belaiche, S. Almer, C. Tysk, C.A. O'Morain, M. Gassull, V. Binder, Y. Finkel, A. Cortot, R. Modigliani, P. Laurent-Puig, C. Gower-Rousseau, J. Macry, J.F. Colombel, M. Sahbatou and G. Thomas (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 599-603.
43. A.F. Hurst (1909) Ulcerative colitis. Guy's Hosp Rep 71 26.
44. N. Inoue, K. Tamura, Y. Kinouchi, Y. Fukuda, S. Takahashi, Y. Ogura, N. Inohara, G. Nunez, Y. Kishi, Y. Koike, T. Shimosegawa, T. Shimoyama and T. Hibi (2002) Lack of common Nod2 variants in Japanese patients with Crohn's disease. Gastroenterology 123 86-91.
45. S.H. Itzkowitz (2004) Colorectal cancer in inflammatory bowel disease: molecular considerations. R.B. Sartor, W.J. Sandborn (Eds) Kirsner's Inflammatory Bowel Diseases New York: Saunders 230-242.
46. S.H. Itzkowitz and N. Harpaz (2004) Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 126 1634-1648.
47. S. Joossens, W. Reinisch, S. Vermeire, B. Sendid, D. Poulain, M. Peeters, K. Geboes, X. Bossuyt, P. Vandewalle, G. Oberhuber, H. Vogelsang, P. Rutgeerts and J.F. Colombel (2002) The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122 1242-1247.
48. H.C. Jung, L. Eckmann, S.K. Yang, A. Panja, J. Fierer, E. Morzycka-Wroblewska and M.F. Kagnoff (1995) A distinct array of proinflamatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J. Clin. Invest. 95 55-65.
49. D. Kaiserlian, K. Vidal and J.P. Revillard (1989) Murine enterocytes can present soluble antigen to specific class II-restricted CD4+T cells. Eur. J. Immunol. 19 1513-1516.
50. J. Kelsen, J. Agnholt, H.J. Hoffmann, J.L. Romer, C.L. Hvas and J.F. Dahlerup (2005) FoxP3+CD4+CD25+ T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol. 141 549-557.
51. S. Kitajima, M. Morimoto, E. Sagara, C. Shimizu and Y. Ikeda (2001) Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. Exp. Anim. 50 387-395.
52. B. Kneitz, T. Herrmann, S. Yonehara and A. Schimpl (1995) Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 25 2572-2577.
53. L.E. Koutroubakis, I.G. Vlachonikolis and E.A. Kouroumalis (2002) Role of appendictis and appendectomy in the pathogenesis of ulcerative colitis: a critical review. Inflamm. Bowel Dis. 8 277-286.
54. T.A. Kraus, L. Toy, L. Chan, J. Childs and L. Mayer (2004) Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease. Gastroenterology 126 1771-1778.
55. R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky and W. Muller (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 263-274.
56. C.J. Landers, O. Cohavy, R. Misra, H. Yang, Y.C. Lin, J. Braun and S.R. Targan (2002) Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123 689-699.
57. S. Lesage, H. Zouali, J.P. Cezard, J.F. Colombel, J. Belaiche, S. Almer, C. Tysk, C. O'Morain, M. Gassull, V. Binder, Y. Finkel, R. Modigliani, C. Gower-Rousseau, J. Macry, F. Merlin, M. Chamaillard, A.S. Jannot, G. Thomas and J.P. Hugot (2002) CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am. J. Hum. Genet. 70 845-857.
58. J.O. Lindsay and H.J. Hodgson (2001) Review article: the immunoregulatory cytokine interleukin-10-a therapy for Crohn's disease? Aliment Pharmacol. Ther. 15 1709-1716.
59. E.V. Loftus (2004) Clinical epidemiology of inflammatory bowel disease. Gastroenterology 126 1504-1517.
60. A. Lugering, M. Schmidt, N. Lugering, H.G. Pauels, W. Domschke and T. Kucharzik (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspasedependent pathway. Gastroenterology 121 1145-1157.
61. R.D. McCall, S. Haskill, E.M. Zimmermann, P.K. Lund, R.C. Thompson and R.B. Sartor (1994) Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 106 960-972.
62. K.L. Madsen, J.S. Doyle, M.M. Tavernini, L.D. Jewell, R.P. Rennie and R.N. Fedorak (2000) Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology 118 1094-1105.
63. Y.R. Mahida, C.E. Lamming, A. Gallagher, A.B. Hawthornne and C.J. Hawkey (1991) 5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 32 50-54.
64. S. Makita, T. Kanai, S. Oshima, K. Uraushihara, T. Totsuka, T. Sawada, T. Nakamura, K. Koganei, T. Fukushima and M. Watanabe (2004) CD4+ CD25brightT cells in human intestinal lamina propria as regulatory cells. J Immunol. 173 3119-3130.
65. P.J. Mannon, I.J. Fuss, L. Mayer, C.O. Elson, W.J. Sandborn, D. Present, B. Dolin, N. Goodman, C. Groden, R.L. Hornung, M. Quezado, M.F. Neurath, J. Salfeld, G.M. Veldman, U. Schwertschlag and W. Strober (2004) Anti-IL-12 Crohn's Disease Study Group Antiinterleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351 2069-2079.
66. S. Matsumoto, Y. Okabe, H. Setoyama, K. Takayama, J. Ohtsuka, H. Funahashi, A. Imaoka, Y. Okada and Y. Umesaki (1998) Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 43 71-78.
67. L. Mayer and R. Shlien (1987) Evidence for function of Ia molecules on gut epithelial cells in man. J. Exp. Med. 166 1471-1483.
68. J.B. Meddings (1997) Review article: Intestinal permeability in Crohn's disease. Aliment. Pharmacol. Ther. 11(Suppl 3), 47-53.
69. P. Mombaerts, E. Mizoguchi, M.J. Grusby, L.H. Glimcher, A.K. Bhan and S. Tonegawa (1993) Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75 274-282.
70. G. Monteleone, L. Biancone, R. Marasco, G. Morrone, O. Marasco, F. Luzza and F. Pallone (1997) Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononu-clear cells. Gastroenterology 112 1169-1178.
71. P.J. Morrissey, K. Charrier, S. Braddy, D. Liggitt and J.D. Watson (1993) CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J. Exp. Med. 178 237-244.
72. K.E. Mostov (1994) Transepithelial transport of immunoglobulins. Ann. Rev. Immunol. 12 63-84.
73. L.P. Mummery (1907) The causes of colitis with special reference to its surgical treatment. With an account of 36 cases. Lancet 1 1638-1643.
74. P. Munkholm and V. Binder (2004) Clinical features and natural history of Crohn's disease. R.B. Sartor, W.J. Sandborn (Eds) Kirsner's Inflammatory Bowel Diseases New York: Saunders 289-300.
75. M. Neurath, I. Fuss and W. Strober (2000) TNBS-colitis. Int. Rev. Immunol. 19 51-62.
76. Y. Ogura, D.K. Bonen, N. Inohara, D.L. Nicolae, F.F. Chen, R. Ramos, H. Britton, T. Moran, R. Karaliuskas, R.H. Duerr, J.P. Achkar, S.R. Brant, T.M. Bayless, B.S. Kirschner, S.B. Hanauer, G. Nunez and J.H. Cho (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 603-606.
77. Y. Ogura, N. Inohara, A. Benito, F.F. Chen, S. Yamaoka and G. Nunez (2001) Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J. Biol. Chem. 276 4812-4818.
78. M. Okada, K. Maeda, T. Yao, A. Iwashita, Y. Nomiyama and K. Kitahara (1991) Minute lesions of the rectum and sigmoid colon in patients with Crohn's disease. Gastrointest. Endosc. 37 319-324.
79. T.R. Orchard and D.P. Jewell (2004) Extraintestinal manifestations: skin, joints, and mucocutaneous manifestations. R.B. Sartor, W.J. Sandborn (Eds) Kirsner's Inflammatory Bowel Diseases New York: Saunders 658-672.
80. M. Orholm, V. Binder, T.I. Sorensen, L.P. Rasmussen and K.O. Kyvik (2000) Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand. J. Gastroenterol. 35 1075-1081.
81. Y. Oyana, R.M. Craig, A.E. Traynor, K. Quigley, L. Statkute, A. Halverson, M. Brush, L. Verda, B. Kowalska, N. Krosnjar, M. Kletzel, P.F. Whitington and R.K. Burt (2005) Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128 552-563.
82. F. Pallone, S. Fais, O. Squarcia, L. Biancone, P. Pozzilli and M. Boirivant (1987) Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut 28 745-753.
83. K.A. Papadakis, O.A. Shaye, E.A. Vasiliauskas, A. Ippoliti, M.C. Dubinsky, J. Birt, J. Paavola, S.K. Lee, J. Price, S.R. Targan and M.T, Abreu (2005) Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol. 100 75-79.
84. M. Peeters, H. Nevens, F. Baert, M. Hiele, A.M. de Meyer, R. Vlietinck and P. Rutgeerts (1996) Familial aggregation in Crohn's disease: increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 111 597-603.
85. V.D. Peltekova, R.F. Wintle, L.A. Rubin, C.I. Amos, Q. Huang, X. Gu, B. Newman, M. Van Oene, D. Cescon, G. Greenberg, A.M. Griffiths, P.H. St George-Hyslop and K.A. Siminovitch (2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet. 36 471-475.
86. D.K. Podolsky (1997) Lessons from genetic models of inflammatory bowel disease. Acta Gastroenterol. Belg. 60 163-165.
87. F. Powrie (1995) T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 3 171-174.
88. D.H. Present, B.I. Korelitz, N. Wisch, J.L. Glass, D.B. Sachar and B.S. Pasternack (1980) Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N. Engl. J. Med. 302 981-987.
89. D.H. Present, P. Rutgeerts, S. Targan, S.B. Hanauer, L. Mayer, R.A. van Hogezand, D.K. Podolsky, B.E. Sands, T. Braakman, K.L, DeWoody, T.F. Schaible and S.J. van Deventer (1999) Infliximab for the-treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340 1398-1405.
90. J.F. Quinton, B. Sendid, D. Reumaux, P. Duthilleul, A. Cortot, B. Grandbastien, G. Charrier, S.R. Targan, J.F. Colombel and D. Poulain (1998) Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42 788-791.
91. H.C. Rath, M. Schultz, R. Freitag, L.A. Dieleman, F. Li, H.J. Linde, J. Scholmerich and R.B. Sartor (2001) Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect. Immun. 69 2277-2285.
92. W. Reinisch, H. Nahavandi, R. Santella, Y. Zhang, C. Gasche, G. Moser, T. Waldhor, A. Gangl, H. Vogelsang and R. Knobler (2001) Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Aliment. Pharmacol. Ther. 15 1313-1322.
93. F.M. Ruemmele, S.R. Targan, G. Levy, M. Dubinsky, J. Braun and E.G. Seidman (1998) Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115 822-829.
94. D.B. Sachar (1994) Cancer in Crohn's disease: dispelling the myths. Gut 35 1507-1508.
95. B. Sadlack, H. Merz, H. Schorle, A. Schimpl, A.C. Feller and I. Horak (1993) Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75 253-261.
96. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, R.D. Baerg, W.J. Tremaine, T. Johnson, N.N. Diehl and A.R. Zinsmeister (2001) Etanercept for active Crohn's disease: a randomized double-blind, placebo-controlled trial. Gastroenterology 121 1088-1094.
97. W.J. Sandbórn, B.G. Feagan, G. Radford-Smith, A. Kovacs, R. Enns, A. Innes and J. Patel (2004) CDP571, a humaised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53 1485-1493.
98. B. Sands (2002) Crohn's disease. M. Feldman, L.S. Friedman, W.O. Tschumy, M.H. Sleisenger (Eds) Sleisenger and Fordtran's Principles of Gastrointestinal Disease New York: Saunders 2005-2038.
99. B.E. Sands, J.E. Arsenault, M.J. Rosen, M. Alsahli, L. Bailen, P. Banks, S. Bensen, A. Bousvaros, D. Cave, J.S. Cooley, H.L. Cooper, S.T. Edwards, R.J. Farrell, M.J. Griffin, D.W. Hay, A. John, S. Lidofsky, L.B. Olans, M.A. Peppercom, R.I. Rothstein, M.A. Roy, M.J. Saletta, S.A. Shah, A.S. Warner, J.L. Wolf, J. Vecchio, H.S. Winter and J.K. Zawacki (2003) Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am.J. Gastro. 98 2712-2718.
100. B.E. Sands, F.H. Anderson, C.N. Bernstein, W.Y. Chey, B.G. Feagan, R.N. Fedorak, M.A. Kamm, J.R. Korzenik, B.A. Lashner, J.E. Onken, D. Rachmilewitz, P. Rutgeerts, G. Wild, D.C. Wolf, P.A. Marsters, S.B. Travers, M.A. Blank and S.J. van Deventer (2004) Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350 876-885.
101. R.B. Sartor, R.A. DeLa Cadena, K.D. Green, A. Stadnicki, S.W. Davis, J.H. Schwab, A.A. Adam, P. Raymond and R.W. Colman (1996) Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 110 1467-1481.
102. R.B. Sartor (2004) Animal models of intestinal inflammation. R.B. Sartor, W.J. Sandborn (Eds) Kirsner's Inflammatory Bowel Diseases New York: Saunders 120-137.
103. J. Satsangi, D.P. Jewell, W.M. Rosenberg and J.I. Bell (1994) Genetics of inflammatory bowel disease. Gut 35 696-700.
104. M. Schultz, S.H. Clarke, L.W. Arnold, R.B. Sartor and S.L. Tonkonogy (2001) Disrupted B-lymphocyte development and survival in interleukin-2-deficient mice. Immunology 104 127-134.
105. D.A. Schwartz, E.V. Loftus Jr., W.J. Tremaine, R. Panaccione, W.S. Harmsen, A.R. Zinsmeister and W.J. Sandborn (2002) The natural history of fistulizing in Crohn's Disease in Olmstead County, Minnesota. Gastroenterology 122 875-880.
106. R.K. Sellon, S. Tonkonogy, M. Schultz, L.A. Dieleman, W. Grenther, E. Balish, D.M. Rennick and R.B. Sartor (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect. Immun. 66 5224-5231.
107. B. Sendid, J.F. Colombel, P.M. Jacquinot, C. Faille, J. Fruit, A. Cortot, D. Lucidarme, D. Camus and D. Poulain (1996) Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin. Diag. Lab. Immunol. 3 219-226.
108. F. Shanahan, A. Niederlehner, N. Carramanzana and P. Anton (1990) Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 20 217-224.
109. A. Sonnenberg, D.J. McCarty and S.J. Jacobsen (1991) Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 100 143-149.
110. P.C. Stokkers, P.H. Reitsma, G.N. Tytgat and S.J. van Deventer (1999) Inflammatory bowel disease and the genes' for the natural resistance-associated macrophage protein-1 and the interferon-gamma receptor 1. Int. J. Colorectal Dis. 14 13-17.
111. M. Stoll, B. Corneliussen, C.M. Costello, G.H. Waetzig, B. Mellgard, W.A. Koch, P. Rosenstiel, M. Albrecht, P.J. Croucher, D. Seegert, S. Nikolaus, J. Hampe, T. Lengauer, S. Pierrou, U.R. Foelsch, C.G. Mathew, M. Lagerstrom-Fermer and S. Schreiber (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat. Genet. 36 476-480.
112. J. Subhani, S. Montgomery, R. Pounder and A. Wakefield (1998) Concordance rates of twins and siblings in inflammatory bowel diseases. Gut 42 A40.
113. J.P. Sundberg, C.O. Elson, H. Bedigian and E.H. Birkenmeier (1994) Spontaneous heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 107 1726-1735.
114. S.R. Targan, S.B. Hanauer, S.J. van Deventer, L. Mayer, D.H. Present, T. Braakman, K.L. DeWoody, T.F. Schaible and P.J. Rutgeerts (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337 1029-1035.
115. S.R. Targan and L.C. Karp (2004) Serology and laboratory markers of disease activity. R.B. Sartor, W.J. Sandborn (Eds) Kirsner's Inflammatory Bowel Diseases New York: Saunders 442-450.
116. K.D. Taylor, S.E. Plevy, H. Yang, C.J. Landers, M.J. Barry, J.I. Rotter and S.R. Targan (2001) ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 120 1347-1355.
117. W.J. Tremaine, S.B. Hanauer, S. Katz, B.D. Winston, J.G. Levine, T. Persson and A. Persson (2002) Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlleld study in the United States. Am. J. Gastroenterol. 97 1748-1754.
118. A. Timmer, L.R. Sutherland and F. Martin (1998) Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. Gastroenterology 114(6), 1143-1150.
119. J.M. Van den Brande, H. Braat, G.R. van den Brink, H.H. Versteeg, C.A. Bauer, I. Hoedemaeker, C. van Montfrans, D.W. Hommes, M.P. Peppelenbosch and S.J. van Deventer (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 1774-1785.
120. E.A. Vasiliauskas, S.E. Plevy, C.J. Landers, S.W. Binder, D.M. Ferguson, H. Yang, J.I. Rotter, A. Vidrich and S.R. Targan (1996) Perinuclear anti-neutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 110 1810-1819.
121. T. Watanabe, A. Kitani, P.J. Murray and W. Strober (2004) NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5 800-808.
122. C. Wells (1952) Ulcerative colitis and Crohn's disease. Ann. R. Surg. Engl. 11 105-120.
123. T. Welte, S.S. Zhang, T. Wang, Z. Zhang, D.G. Hesslein, Z. Yin, A. Kano, Y. Iwamoto, E. Li, J.E. Craft, A.L. Bothwell, E. Fikrig, P.A. Koni, R.A. Flavell and X.Y. Fu (2003) STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. U.S.A. 100 1879-1884.
124. S. Wilks (1859) 3rd ed. Lectures on Pathological Anatomy London: Longmans
125. T.A. Winter, J. Wright, S. Ghosh, J. Jahnsen, A. Innes and P. Round (2004) Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-tosevere Crohn's disease: an exploratory study. Aliment. Pharmacol. Ther. 20 1337-1346.
126. T. Yamamoto, S. Umegae, T. Kitagawa, Y. Yasuda, Y. Yamada, D. Takahashi, M. Mukumoto, N. Nishimura, K. Yasue and K. Matsumoto (2004) Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment. Pharmacol. Ther. 20 783-792.